Advertisement
Advertisement
TBPH
Theravance Biopharma, Inc.
16.25
USDSponsored
-0.01
-0.06%
May 19, 15:59 UTC -4
Closed
Pre-Market
16.25
0.00
+0.03%
TBPH Earnings Reports
Positive Surprise Ratio
TBPH beat 18 of 42 last estimates.
43%
Next Report
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$22.24M
/$0.04
Implied change from Q1 26 (Revenue/ EPS)
+25.63%
/-233.33%
Implied change from Q2 25 (Revenue/ EPS)
-15.11%
/-107.41%
Theravance Biopharma, Inc. earnings per share and revenue
On May 07, 2026, TBPH reported earnings of -0.03 USD per share (EPS) for Q1 26, beating the estimate of -0.14 USD, resulting in a 79.48% surprise. Revenue reached 17.70 million, compared to an expected 17.54 million, with a 0.88% difference. The market reacted with a +0.47% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 7 analysts forecast an EPS of 0.04 USD, with revenue projected to reach 22.24 million USD, implying an decrease of -233.33% EPS, and increase of 25.63% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ARS Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.53
Actual
-$0.61
Surprise
-13.81%
ProKidney Corp. Class A Ordinary Shares
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+0.57%
Galectin Therapeutics Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.06
Actual
-$0.08
Surprise
-30.72%
NRX Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
$0.29
Actual
-$0.04
Surprise
-113.64%
Incannex Healthcare Limited - ADR
Report Date
May 15, 2026 For Q3 26
Estimate
-$0.94
Actual
-$11.22
Surprise
-1088.38%
PLUS THERAPEUTICS, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.89
Actual
-$1.05
Surprise
-16.98%
VYNE Therapeutics Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.08
Surprise
+56.43%
Scienture Holdings, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.08
Surprise
+64.35%
Wellgistics Health, Inc. Common Stock
Report Date
May 19, 2026 For Q1 26
Estimate
-Actual
-$0.07
Surprise
-
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.77
Actual
-$1.28
Surprise
-65.12%
FAQ
What were Theravance Biopharma, Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Theravance Biopharma, Inc. reported EPS of -$0.03, beating estimates by 79.48%, and revenue of $17.70M, 0.88% above expectations.
How did the market react to Theravance Biopharma, Inc.'s Q1 2026 earnings?
The stock price moved up 0.47%, changed from $16.94 before the earnings release to $17.02 the day after.
When is Theravance Biopharma, Inc. expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for Theravance Biopharma, Inc.'s next earnings report?
Based on 7
analysts, Theravance Biopharma, Inc. is expected to report EPS of $0.04 and revenue of $22.24M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement